


UD PCS clinical trials management online class starts Sept. 11
Graphic by Cindy Dolan August 10, 2023
Online course focuses on high-profile field of clinical and pharmaceutical research
The University of Delaware’s long-running Clinical Trials Management Certificate program, now in its 16th year, has seen increased enrollment in recent years. Previously offered twice annually, a third cohort has been added each year since the start of the pandemic in 2020, when media attention made “clinical trials” a household word. The next 14-week online course starts Sept. 11.
“Clinical research is a field that attracts individuals who have a passion for investigating and finding outcomes that make an impact on an individual's healthcare status,” said Michele Welch, a clinical research professional with over 22 years of global product development experience and the program director.
Career opportunities in the clinical research field are varied, including settings in pharmaceutical and biotechnology companies, medical device manufacturers, contract research organizations (CROs), clinical facilities and academic institutions.
Many professionals with a strong science- or healthcare-related background, such as nurses, pharmacists, medical technologists and physicians, are well positioned to join the clinical research field, as are associated professionals from fields like marketing, project management and data analysis.
Offered through UD’s Division of Professional and Continuing Studies (UD PCS), the self-paced Clinical Trials Management curriculum includes broad coverage of U.S. and worldwide clinical trial processes and regulations, data management, legal and ethical considerations and marketing principles.
UD students, UD alumni, military veterans and personnel, and others are eligible for a discount when enrolling in this program. A payment plan and scholarship opportunities are available.
For more information, visit the website.
Contact Us
Have a UDaily story idea?
Contact us at ocm@udel.edu
Members of the press
Contact us at 302-831-NEWS or visit the Media Relations website